M&A / Deals Odyssey launches upsized $279M IPO, Seaport docks on Nasdaq BioSpaceAnalysts are cautiously optimistic about an IPO rebound for biopharma.Read full story pharminent May 8, 2026 (Last updated: May 10, 2026) BioSpace Analysts are cautiously optimistic about an IPO rebound for biopharma. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Novo’s CEO champions “record-breaking start” for Wegovy pill in US marketNext: Biogen, Eisai hit with 3-month delay for starting SubQ Alzheimer’s therapy Related Stories M&A / Deals AbbVie climbs post-Allergan M&A peak with Apogee buy pharminent June 22, 2026 M&A / Deals Lilly bets up to $800M for BioArctic’s brain delivery tech pharminent June 22, 2026 M&A / Deals Insilico and SK Bio forge $2.5bn AI neuroimmunity alliance pharminent June 22, 2026
